LMO3

Summary

LMO3 (LIM domain only 3, HGNC:6643) is a protein-coding gene on chromosome 12p12.3, encoding LIM domain only protein 3 (Q8TAP4).

The protein encoded by this gene belongs to the rhombotin family of cysteine-rich LIM domain oncogenes. This gene is predominantly expressed in the brain. Related family members, LMO1 and LMO2 on chromosome 11, have been reported to be involved in chromosomal translocations in T-cell leukemia. Many alternatively spliced transcript variants have been found for this gene.

Source: NCBI Gene 55885 — RefSeq curated summary.

At a glance

• GWAS associations: 9
• Clinical variants (ClinVar): 13 total
• MANE Select transcript: NM_018640

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:6643
Approved symbol	LMO3
Name	LIM domain only 3
Location	12p12.3
Locus type	gene with protein product
Status	Approved
Aliases	Rhom-3, DAT1
Ensembl gene	ENSG00000048540
Ensembl biotype	protein_coding
OMIM	180386
Entrez	55885

Gene structure

Transcript identifiers

Ensembl transcripts: 58 — 44 protein_coding, 8 nonsense_mediated_decay, 4 protein_coding_CDS_not_defined, 2 retained_intron

ENST00000261169, ENST00000320122, ENST00000332914, ENST00000354662, ENST00000396205, ENST00000424192, ENST00000439600, ENST00000441439, ENST00000447609, ENST00000453727, ENST00000534946, ENST00000535535, ENST00000536172, ENST00000536509, ENST00000537304, ENST00000537568, ENST00000537757, ENST00000538020, ENST00000538051, ENST00000539232, ENST00000539534, ENST00000540445, ENST00000540590, ENST00000540848, ENST00000541295, ENST00000541589, ENST00000541764, ENST00000541846, ENST00000543721, ENST00000544276, ENST00000544754, ENST00000545436, ENST00000546279, ENST00000546281, ENST00000872904, ENST00000872905, ENST00000872906, ENST00000872907, ENST00000872908, ENST00000872909, ENST00000872910, ENST00000872911, ENST00000872912, ENST00000872913, ENST00000872914, ENST00000872915, ENST00000872916, ENST00000872917, ENST00000872918, ENST00000926579, ENST00000926580, ENST00000926581, ENST00000926582, ENST00000926583, ENST00000954699, ENST00000954700, ENST00000954701, ENST00000954702

RefSeq mRNA: 7 — MANE Select: NM_018640 NM_001001395, NM_001243609, NM_001243610, NM_001243611, NM_001243612, NM_001243613, NM_018640

CCDS: CCDS58210, CCDS58211, CCDS58212, CCDS8678

Canonical transcript exons

ENST00000537304 — 4 exons

Exon	Start	End
ENSE00001524225	16606066	16606162
ENSE00002300197	16548372	16551327
ENSE00003468813	16600655	16600868
ENSE00003786546	16560413	16560538

Expression profiles

Bgee: expression breadth ubiquitous, 249 present calls, max score 99.58.

FANTOM5 (CAGE): breadth broad, TPM avg 12.8004 / max 1133.9355, expressed in 536 samples.

FANTOM5 promoters (32 alternative TSS)

Promoter ID	TPM avg	Samples expressed
129970	4.8371	392
129958	1.4134	268
129981	1.2140	162
129971	0.8065	204
129972	0.6432	120
129977	0.5447	207
129966	0.4435	170
129959	0.3089	132
129984	0.2880	55
129960	0.2556	135

Top tissues by expression

297 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
middle temporal gyrus	UBERON:0002771	99.58	gold quality
Brodmann (1909) area 46	UBERON:0006483	99.30	gold quality
Brodmann (1909) area 23	UBERON:0013554	99.19	gold quality
orbitofrontal cortex	UBERON:0004167	99.18	gold quality
superior frontal gyrus	UBERON:0002661	99.11	gold quality
entorhinal cortex	UBERON:0002728	99.05	gold quality
endothelial cell	CL:0000115	99.04	gold quality
cortical plate	UBERON:0005343	99.02	gold quality
postcentral gyrus	UBERON:0002581	98.77	gold quality
parietal lobe	UBERON:0001872	98.55	gold quality
cranial nerve II	UBERON:0000941	98.54	gold quality
temporal lobe	UBERON:0001871	98.04	gold quality
nucleus accumbens	UBERON:0001882	97.97	gold quality
dorsal motor nucleus of vagus nerve	UBERON:0002870	97.97	gold quality
CA1 field of hippocampus	UBERON:0003881	97.97	gold quality
caudate nucleus	UBERON:0001873	97.86	gold quality
calcaneal tendon	UBERON:0003701	97.84	gold quality
prefrontal cortex	UBERON:0000451	97.83	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	97.73	gold quality
primary visual cortex	UBERON:0002436	97.60	gold quality
Brodmann (1909) area 9	UBERON:0013540	97.57	gold quality
amygdala	UBERON:0001876	97.54	gold quality
putamen	UBERON:0001874	97.51	gold quality
frontal cortex	UBERON:0001870	97.42	gold quality
frontal lobe	UBERON:0016525	97.42	gold quality
telencephalon	UBERON:0001893	97.39	gold quality
cerebral cortex	UBERON:0000956	97.38	gold quality
neocortex	UBERON:0001950	97.25	gold quality
occipital lobe	UBERON:0002021	97.16	gold quality
cingulate cortex	UBERON:0003027	96.51	gold quality

Single-cell (SCXA)

Detected in 9 experiment(s), a significant marker in 9.

Experiment	Marker?	Max mean expression
E-HCAD-5	yes	1153.94
E-MTAB-9154	yes	677.85
E-MTAB-8894	yes	580.28
E-MTAB-8530	yes	214.00
E-GEOD-98556	yes	183.29
E-ANND-3	yes	22.44
E-HCAD-1	yes	20.64
E-GEOD-130148	yes	10.09
E-ENAD-27	yes	4.10

Regulation

Is transcription factor: yes

Downstream targets (CollecTRI)

2 targets.

Target	Regulation
ASCL1	Activation
HES1	Repression

Upstream regulators (CollecTRI, top): ARX, EBF3, EGR1, ETS2, GBX2, LHX2, LHX9, NKX2-1, NR3C1, TP53

miRNA regulators (miRDB)

137 targeting LMO3, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3924	100.00	72.09	2394
HSA-LET-7A-3P	100.00	74.03	3932
HSA-LET-7B-3P	100.00	74.08	3913
HSA-LET-7F-1-3P	100.00	74.02	3928
HSA-MIR-98-3P	100.00	74.08	3907
HSA-MIR-4262	100.00	73.26	3931
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-6867-5P	100.00	82.21	3464
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-3662	99.99	73.82	5684
HSA-MIR-548P	99.98	72.25	3784
HSA-MIR-4775	99.98	75.00	6394
HSA-LET-7F-2-3P	99.98	70.98	2588
HSA-MIR-1185-1-3P	99.98	71.04	2593
HSA-MIR-1185-2-3P	99.98	71.04	2593
HSA-MIR-520D-5P	99.98	73.34	4883
HSA-MIR-524-5P	99.98	73.43	4882
HSA-MIR-3148	99.97	75.06	6478
HSA-MIR-548AT-5P	99.96	70.83	2666
HSA-MIR-590-3P	99.96	74.34	6478
HSA-MIR-4666A-3P	99.96	71.71	3434
HSA-MIR-302E	99.96	70.74	2669
HSA-MIR-9-3P	99.96	70.88	2068
HSA-MIR-141-3P	99.94	72.79	2421
HSA-MIR-200A-3P	99.94	72.68	2420
HSA-MIR-381-3P	99.93	71.87	2854
HSA-MIR-218-5P	99.93	72.22	2103
HSA-MIR-300	99.92	71.76	2856
HSA-MIR-10527-5P	99.91	72.28	3754

Literature-anchored findings (GeneRIF, showing 18)

• The deregulated expression of neuronal-specific LMO3 and HEN2 contributes to the genesis and progression of human neuroblastoma in a lineage-specific manner. (PMID:15930276)
• LMO3 acts as a co-repressor of p53, suppressing p53-dependent transcriptional regulation without inhibition of its DNA-binding activity. (PMID:19995558)
• The present results suggest that a transcriptional complex of LMO3 and HEN2 may contribute to the genesis and malignant phenotype of neuroblastoma by inhibiting HES1 which suppresses the transactivation of Mash1. (PMID:21573214)
• We confirmed that the expression of LMO3 in squamous cell carcinoma is regulated by DNA methylation of its specific promoter region. (PMID:22011669)
• suggest that LMO3 is a transcriptional signal transducer in NKX2-1-amplified lung adenocarcinomas (PMID:23322301)
• LMO3 as a regulator of human adipogenesis and could contribute a mechanism resulting in visceral-fat accumulation in obesity due to excess glucocorticoids. (PMID:23823477)
• MiR-101 decreased the expression of LMO3 by reversing the methylation status of the LMO3 promoter and by inhibiting the presence of the methylation-related histones H3K4me2 and H3K27me3 and increasing the presence of H3K9me3 and H4K20me3 on the promoter. (PMID:25829251)
• SH3BP5, LMO3, and SNAP25 were expressed in diffuse large B-cell lymphoma cells and associated with clinical features. (PMID:27184832)
• LMO3 attenuates GATA4-dependent, BMP2-mediated inflammatory endothelial activation. (PMID:28669928)
• These results suggested that LMO3 promotes Gastric Cancer cell invasion and proliferation mainly through Akt/mTOR and Akt/GSK3beta signaling. (PMID:29436606)
• These results suggest that LMO3 promotes hepatocellular carcinoma (HCC) cell invasion and anoikis inhibition by interacting with LATS1 and suppressing Hippo signaling. LMO3 may serve as a potential therapeutic target for HCC in future (PMID:30219064)
• our results suggest that LMO3-BORCS5 fusion oncogene plays an essential role in tumorigenesis (PMID:31488873)
• MicroRNA-381 inhibits lung adenocarcinoma cell biological progression by directly targeting LMO3 through regulation of the PI3K/Akt signaling pathway and epithelial-to-mesenchymal transition. (PMID:31646571)
• LMO3 reprograms visceral adipocyte metabolism during obesity. (PMID:34018016)
• Transcriptomic analysis and biological evaluation reveals that LMO3 regulates the osteogenic differentiation of human adipose derived stem cells via PI3K/Akt signaling pathway. (PMID:35165791)
• Hyperglycemia affects neuronal differentiation and Nestin, FOXO1, and LMO3 mRNA expression of human Wharton’s jelly mesenchymal stem cells of children from diabetic mothers. (PMID:36413852)
• Circ_0007385 promotes the proliferation and inhibits the apoptosis of non-small cell lung cancer cells via miR-337-3p-dependent regulation of LMO3. (PMID:36426731)
• LMO3 is a suppressor of the basal-like/squamous subtype and reduces disease aggressiveness of pancreatic cancer through glycerol 3-phosphate metabolism. (PMID:38366633)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	lmo3	ENSDARG00000008720
mus_musculus	Lmo3	ENSMUSG00000030226
rattus_norvegicus	Lmo3	ENSRNOG00000047450

Paralogs (20): FHL1 (ENSG00000022267), LHX5 (ENSG00000089116), ZFHX4 (ENSG00000091656), LHX2 (ENSG00000106689), LHX6 (ENSG00000106852), LHX3 (ENSG00000107187), LHX4 (ENSG00000121454), LMO2 (ENSG00000135363), ZFHX2 (ENSG00000136367), LMX1B (ENSG00000136944), ZFHX3 (ENSG00000140836), LMO4 (ENSG00000143013), LHX9 (ENSG00000143355), CRIP3 (ENSG00000146215), LHX8 (ENSG00000162624), LMX1A (ENSG00000162761), LMO1 (ENSG00000166407), CRIP2 (ENSG00000182809), CRIP1 (ENSG00000213145), LHX1 (ENSG00000273706)

Protein

Protein identifiers

LIM domain only protein 3 — Q8TAP4 (reviewed: Q8TAP4)

Alternative names: Neuronal-specific transcription factor DAT1, Rhombotin-3

All UniProt accessions (11): C9JE61, Q8TAP4, F5GYZ6, F5GZR3, F5H2N9, F5H3S4, F5H4K9, F5H4T0, F5H655, F6TDU8, Q05D86

Isoforms (4)

UniProt ID	Names	Canonical?
Q8TAP4-1	1	yes
Q8TAP4-2	2
Q8TAP4-3	3
Q8TAP4-4	4

RefSeq proteins (7): NP_001001395, NP_001230538, NP_001230539, NP_001230540, NP_001230541, NP_001230542, NP_061110* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001781	Znf_LIM	Domain
IPR050945	LMO_RBTN_TF	Family

Pfam: PF00412

UniProt features (7 total): splice variant 3, domain 2, chain 1, sequence conflict 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q8TAP4-F1	88.38	0.79

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 301 (showing top): GOBP_NEGATIVE_REGULATION_OF_ERK1_AND_ERK2_CASCADE, YAATNRNNNYNATT_UNKNOWN, GOBP_REGULATION_OF_FAT_CELL_DIFFERENTIATION, FREAC2_01, RORA1_01, GOBP_CELLULAR_RESPONSE_TO_LIPID, NKX25_02, GCANCTGNY_MYOD_Q6, CMYB_01, GOBP_POSITIVE_REGULATION_OF_FAT_CELL_DIFFERENTIATION, AREB6_03, GOBP_POSITIVE_REGULATION_OF_INTRACELLULAR_STEROID_HORMONE_RECEPTOR_SIGNALING_PATHWAY, GOBP_REGULATION_OF_INTRACELLULAR_STEROID_HORMONE_RECEPTOR_SIGNALING_PATHWAY, TGACCTY_ERR1_Q2, TACAATC_MIR508

GO Biological Process (5): positive regulation of peroxisome proliferator activated receptor signaling pathway (GO:0035360), positive regulation of fat cell differentiation (GO:0045600), positive regulation of transcription by RNA polymerase II (GO:0045944), negative regulation of ERK1 and ERK2 cascade (GO:0070373), positive regulation of nuclear receptor-mediated glucocorticoid signaling pathway (GO:2000324)

GO Molecular Function (4): transcription coactivator activity (GO:0003713), metal ion binding (GO:0046872), DNA-binding transcription factor binding (GO:0140297), protein binding (GO:0005515)

GO Cellular Component (2): nucleus (GO:0005634), cytoplasm (GO:0005737)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
positive regulation of DNA-templated transcription	2
peroxisome proliferator activated receptor signaling pathway	1
regulation of peroxisome proliferator activated receptor signaling pathway	1
positive regulation of intracellular signal transduction	1
fat cell differentiation	1
positive regulation of cell differentiation	1
regulation of fat cell differentiation	1
regulation of transcription by RNA polymerase II	1
transcription by RNA polymerase II	1
negative regulation of MAPK cascade	1
ERK1 and ERK2 cascade	1
regulation of ERK1 and ERK2 cascade	1
positive regulation of intracellular steroid hormone receptor signaling pathway	1
nuclear receptor-mediated glucocorticoid signaling pathway	1
regulation of nuclear receptor-mediated glucocorticoid signaling pathway	1
transcription coregulator activity	1
cation binding	1
transcription factor binding	1
binding	1
intracellular membrane-bounded organelle	1
intracellular anatomical structure	1
cellular anatomical structure	1

Protein interactions and networks

STRING

0 interactions, top by confidence (×1000):

IntAct

71 interactions, top by confidence:

A	B	Type	Score
LMO3	FBLIM1	psi-mi:“MI:0915”(physical association)	0.670
LDB1	LMO3	psi-mi:“MI:0915”(physical association)	0.670
LMO3		psi-mi:“MI:0915”(physical association)	0.560
SP4	LMO3	psi-mi:“MI:0915”(physical association)	0.560
LMO3	IKZF1	psi-mi:“MI:0915”(physical association)	0.560
FOS	LMO3	psi-mi:“MI:0915”(physical association)	0.560
KCTD1	LMO3	psi-mi:“MI:0915”(physical association)	0.560
LMO3	TAX1BP1	psi-mi:“MI:0915”(physical association)	0.560
NUTM1	LMO3	psi-mi:“MI:0915”(physical association)	0.560
CEP57L1	LMO3	psi-mi:“MI:0915”(physical association)	0.560
SAMD3	LMO3	psi-mi:“MI:0915”(physical association)	0.560
BANP	LMO3	psi-mi:“MI:0915”(physical association)	0.560
LMO3	CBY2	psi-mi:“MI:0915”(physical association)	0.560
LMO3	FAM131C	psi-mi:“MI:0915”(physical association)	0.560
	LMO3	psi-mi:“MI:0915”(physical association)	0.560
LMO3	NUTM1	psi-mi:“MI:0915”(physical association)	0.560
LMO3	SAMD3	psi-mi:“MI:0915”(physical association)	0.560

BioGRID (164): LMO3 (Two-hybrid), LMO3 (Two-hybrid), LMO3 (Two-hybrid), LMO3 (Two-hybrid), LMO3 (Two-hybrid), LMO3 (Two-hybrid), LMO3 (Two-hybrid), CCDC33 (Two-hybrid), SAMD3 (Two-hybrid), SPERT (Two-hybrid), NUTM1 (Two-hybrid), KCTD1 (Two-hybrid), NBPF22P (Two-hybrid), CEP57L1 (Two-hybrid), FAM131C (Two-hybrid)

ESM2 similar proteins: A0A324, A1XQR9, A4FUI2, A5JSS2, A6MZM2, G1SHQ2, O09167, O14602, O35900, O60739, P20280, P25800, P41567, P46778, P47813, P48024, P49666, P51971, P61220, P62303, P62304, P62305, P62308, P62309, Q09028, Q0D5W6, Q0P5B3, Q2KIA3, Q3B8H4, Q3ZBL0, Q4R4X9, Q503U0, Q5E938, Q5RA42, Q5RBW7, Q5RFF4, Q60872, Q60972, Q6GVM3, Q6QN05

Diamond homologs: A0JNI8, A2I8Z7, A2PZF9, G5EC36, G5EE86, O14639, O35652, O60663, O88609, O94929, O97581, P20154, P25791, P25800, P25801, P29673, P29674, P34764, P34765, P36198, P36200, P37137, P48742, P50211, P50212, P50458, P50480, P50481, P52889, P53405, P53406, P53407, P53408, P53409, P53410, P53411, P53412, P53413, P53667, P53668

SIGNOR signaling

3 interactions.

A	Effect	B	Mechanism
LMO3	“up-regulates quantity by expression”	ASCL1	“transcriptional regulation”
LMO3	“down-regulates quantity by repression”	HES1	“transcriptional regulation”
LMO3	“up-regulates activity”	NHLH2	binding

Disease & clinical

Clinical variants and AI predictions

ClinVar

13 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	9
Likely benign	1
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

1319 predictions. Top by Δscore:

Variant	Effect	Δscore
12:16560408:CTTA:C	donor_loss	1.0000
12:16560409:TTAC:T	donor_loss	1.0000
12:16560410:TA:T	donor_loss	1.0000
12:16560411:A:C	donor_loss	1.0000
12:16560412:CCT:C	donor_gain	1.0000
12:16560535:GAGCC:G	acceptor_loss	1.0000
12:16560537:GC:G	acceptor_gain	1.0000
12:16560537:GCCTA:G	acceptor_loss	1.0000
12:16560538:CC:C	acceptor_gain	1.0000
12:16560538:CCT:C	acceptor_loss	1.0000
12:16560539:C:CA	acceptor_loss	1.0000
12:16560539:C:CC	acceptor_gain	1.0000
12:16560540:T:A	acceptor_loss	1.0000
12:16590509:A:AC	donor_gain	1.0000
12:16600746:T:TA	donor_gain	1.0000
12:16600864:TATAC:T	acceptor_gain	1.0000
12:16600865:ATAC:A	acceptor_gain	1.0000
12:16600866:TAC:T	acceptor_gain	1.0000
12:16600866:TACC:T	acceptor_loss	1.0000
12:16600869:C:CC	acceptor_gain	1.0000
12:16600869:CTAAA:C	acceptor_loss	1.0000
12:16560411:A:AC	donor_gain	0.9900
12:16560412:C:CC	donor_gain	0.9900
12:16560535:GAGC:G	acceptor_gain	0.9900
12:16600688:G:C	donor_gain	0.9900
12:16600729:G:C	donor_gain	0.9900
12:16600867:AC:A	acceptor_gain	0.9900
12:16600868:CC:C	acceptor_gain	0.9900
12:16560534:AGAGC:A	acceptor_gain	0.9800
12:16600727:CAG:C	donor_gain	0.9800

AlphaMissense

0 scored. Top likely-pathogenic:

dbSNP variants (sampled 300 via entrez): RS1000057979 (12:16571474 A>C,G), RS1000114524 (12:16597654 T>G), RS1000149954 (12:16553826 G>C), RS1000166838 (12:16598084 T>C), RS1000198643 (12:16597521 G>A), RS1000321476 (12:16590844 C>A,T), RS1000357048 (12:16584294 T>C), RS1000363048 (12:16577517 T>C), RS1000451951 (12:16583831 T>C), RS1000497894 (12:16610675 A>C), RS1000579223 (12:16578368 T>C), RS1000606781 (12:16554270 T>C), RS1000668593 (12:16597222 A>G,T), RS1000738511 (12:16571847 T>C), RS1000742910 (12:16560095 A>G,T)

Disease associations

OMIM: gene MIM:180386 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

9 associations (top):

Study	Trait	p-value
GCST006946_11	Worry too long after an embarrassing experience	8.000000e-10
GCST007277_16	Tourette syndrome	1.000000e-06
GCST007576_138	Chronotype	2.000000e-10
GCST009524_200	Household income (MTAG)	6.000000e-09
GCST011461_2	Barrett’s esophagus or Esophageal adenocarcinoma	1.000000e-08
GCST011461_7	Barrett’s esophagus or Esophageal adenocarcinoma	5.000000e-09
GCST011462_2	Barrett’s esophagus or esophageal adenocarcinoma x sex interaction (2df test)	4.000000e-08
GCST011584_1	Metastatic colorectal cancer survival in treatment with chemotherapy plus biologics	1.000000e-06
GCST011703_7	Smoking initiation	2.000000e-08

EFO canonical traits (7, from GWAS)

EFO ID	Trait name
EFO:0009589	worry measurement
EFO:0008328	chronotype measurement
EFO:0009695	household income
EFO:0008343	sex interaction measurement
EFO:0000714	survival time
EFO:1001480	metastatic colorectal cancer
EFO:0005670	smoking initiation

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

43 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects expression, increases methylation, affects cotreatment, decreases expression	8
methylmercuric chloride	decreases expression	3
trichostatin A	affects cotreatment, decreases expression	3
Dexamethasone	affects cotreatment, increases expression	3
Estradiol	decreases expression	3
Ethinyl Estradiol	affects expression, decreases expression	3
mercuric bromide	decreases expression, affects cotreatment	2
entinostat	decreases expression, affects cotreatment	2
belinostat	decreases expression, affects cotreatment	2
Panobinostat	affects cotreatment, decreases expression	2
Nickel	decreases expression	2
Phenylmercuric Acetate	affects cotreatment, decreases expression	2
1-Methyl-3-isobutylxanthine	affects cotreatment, increases expression	2
Genistein	decreases expression	2
p-Chloromercuribenzoic Acid	affects cotreatment, decreases expression	2
bisphenol A	affects expression	1
arsenite	increases methylation	1
sodium arsenite	decreases expression	1
tetrabromobisphenol A	increases expression	1
tobacco tar	decreases expression, decreases reaction	1
allyl sulfide	decreases expression, decreases reaction	1
beta-methylcholine	affects expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, decreases expression	1
dorsomorphin	decreases expression, affects cotreatment	1
Temozolomide	increases expression	1
Sunitinib	decreases expression	1
Benzo(a)pyrene	decreases methylation, affects methylation	1
Dichlorodiphenyl Dichloroethylene	increases expression	1
Diethylhexyl Phthalate	decreases expression	1
Indomethacin	increases expression, affects cotreatment	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.